Kornam, tablets 5 mg 30 pcs

Cornam is a blocker of peripheral postsynaptic a₁ adrenoreceptors.

Induces dilation of arterioles and venules, decreases OPPS and venous return to the heart, resulting in a decrease of BP.

The hypotensive effect lasts for 24 hours after a single dose of the drug.

Blocking a₁ adrenoreceptors of smooth muscles of prostate and bladder neck promotes normalization of urination in patients with benign prostatic hyperplasia.

The drug helps normalize lipid metabolism: it reduces cholesterol, triglycerides and low and very low density lipoproteins in the blood while increasing the amount of high density lipoproteins.

With systematic use of Kornam there is regression of left ventricular hypertrophy.

Indications

Benign prostatic hyperplasia.
Arterial hypertension.

Pharmacological effect

Cornam is a blocker of peripheral postsynaptic a1-adrenergic receptors.

Causes expansion of arterioles and venules, reduces peripheral vascular resistance and venous return to the heart, resulting in a decrease in blood pressure.

After taking a single dose of the drug, the hypotensive effect persists for 24 hours.

By blocking a1-adrenergic receptors of the smooth muscles of the prostate gland and bladder neck, the drug helps normalize urination in patients with benign prostatic hyperplasia.

The drug helps normalize lipid metabolism: reduces the content of cholesterol, triglycerides and low- and very low-density lipoproteins in the blood, while increasing the amount of high-density lipoproteins.

With systematic use of Kornam, regression of left ventricular hypertrophy is noted.

Special instructions

To prevent the development of orthostatic arterial hypotension, treatment should begin with the appointment of Kornam at a dose of 1 mg/day. before going to bed, after which the patient should remain in bed for 6-8 hours.

The risk of orthostatic arterial hypotension (“first dose effect”) is highest within 30-90 minutes after taking the drug and is increased in patients simultaneously receiving beta-blockers and diuretics, with a decrease in blood volume, a low-salt diet, and also when resuming treatment with the drug after a break (several days).

In case of temporary cessation of treatment, therapy is resumed at the same dose. During treatment, the level of prostate specific antigen does not change. Before starting therapy for benign prostatic hyperplasia, it is necessary to exclude prostate cancer.

The patient should be informed about the increased risk of orthostatic hypotension when drinking alcohol, standing or exercising for long periods of time, or in hot weather.

Within 12 hours after taking the first dose, after increasing the dose or interrupting therapy, it is not recommended to engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Active ingredient

Terazosin

Composition

1 tablet contains:

Terazosin (in the form of hydrochloride dihydrate) 5 mg.

Excipients:

lactose monohydrate,

microcrystalline cellulose,

corn starch,

talc,

yellow dye (E104),

anhydrous colloidal silicon dioxide,

magnesium stearate.

Pregnancy

Cornam can be used during pregnancy and breastfeeding if the potential benefit to the mother outweighs the possible risk to the fetus or infant.

Contraindications

Childhood.
Hypersensitivity to the drug.

The drug should be prescribed with caution in case of angina pectoris, ischemic heart disease, liver or kidney failure, cerebrovascular accident, type 1 diabetes mellitus.

Side Effects

In the treatment of benign prostatic hyperplasia

From the cardiovascular system: rarely – orthostatic hypotension.

From the central nervous system: drowsiness, dizziness, asthenia.

Other: nasal congestion.

In the treatment of arterial hypertension

From the cardiovascular system: orthostatic hypotension – “first dose effect” (observed in 1% of patients, mainly receiving simultaneously diuretics or beta-blockers), manifested by dizziness, tachycardia, possible fainting; rarely – palpitations, peripheral edema, nasal congestion.

From the side of the central nervous system: rarely – dizziness, asthenia, drowsiness, impaired clarity of visual perception.

From the hematopoietic system: decrease (associated with hemodilution) of hematocrit, hemoglobin, leukopenia, hypoproteinemia, hypoalbuminemia.

Other: rarely – decreased potency, nausea.

Interaction

With simultaneous use of Kornam and beta-blockers, diuretics, calcium channel blockers, ACE inhibitors, the antihypertensive effect may be enhanced. Particular caution is required when prescribing terazosin and centrally acting antihypertensive drugs simultaneously.

The absorption of terazosin is reduced when taking adsorbents and antacids simultaneously.

Adrenergic agonists weaken the effect of terazosin.

With the simultaneous use of terazosin and NSAIDs, a decrease in the antihypertensive effect is possible due to suppression of prostaglandin synthesis and fluid and sodium ion retention.

Overdose

Symptoms: marked decrease in blood pressure, impaired coordination of movements, fainting.

Treatment: it is necessary to lay the patient down with the head end of the bed down.

If necessary, prescribe hypertensive drugs and intravenous fluid administration.

Hemodialysis is not effective.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Lek d.d., Slovenia